Skip to content
Wenlo
Sign in
← Markets

Regeneron Pharmaceuticals, Inc.

Christine A Poon (Director) sells REGN shares

4REGNFiled Nov 4, 2026, 4:09 PM ET· Period Nov 2, 2026

AI-generated summary

Director Christine A Poon exercised options for 7,830 shares of common stock at an average price of $376.69, valued at $2,949,482.70. Christine A Poon also sold 7,830 shares of common stock at an average price of $969.09, for a total value of $7,587,957.78. After these transactions, Christine A Poon directly held 5,219 shares of common stock.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Christine A Poon · Director
DateTransactionSharesPriceValueHeld afterOwnership
Nov 2, 2026M · exercise or conversion of a derivative+7,830$376.69$2,949,482.7013,049Direct
Nov 2, 2026S · open-market saleFootnotes F1−218$966.74$210,749.3212,831Direct
Nov 2, 2026S · open-market saleFootnotes F2−772$967.38$746,817.3612,059Direct
Nov 2, 2026S · open-market saleFootnotes F3−2,499$968.58$2,420,481.429,560Direct
Nov 2, 2026S · open-market saleFootnotes F4−3,203$969.50$3,105,308.506,357Direct
Nov 2, 2026S · open-market saleFootnotes F5−937$970.51$909,367.875,420Direct
Nov 2, 2026S · open-market saleFootnotes F6−201$971.31$195,233.315,219Direct
Nov 2, 2026M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F7−7,830$0.00$0.000Direct
Footnotes
  1. F1 Represents volume-weighted average price of sales of 218 shares of Company stock on November 2, 2026 at prices ranging from $966.39 to $966.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
  2. F2 Represents volume-weighted average price of sales of 772 shares of Company stock on November 2, 2026 at prices ranging from $967.06 to $967.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
  3. F3 Represents volume-weighted average price of sales of 2,499 shares of Company stock on November 2, 2026 at prices ranging from $968.00 to $968.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
  4. F4 Represents volume-weighted average price of sales of 3,203 shares of Company stock on November 2, 2026 at prices ranging from $969.01 to $969.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
  5. F5 Represents volume-weighted average price of sales of 937 shares of Company stock on November 2, 2026 at prices ranging from $970.00 to $970.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
  6. F6 Represents volume-weighted average price of sales of 201 shares of Company stock on November 2, 2026 at prices ranging from $971.16 to $971.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
  7. F7 The stock option vested in three equal annual installments, commencing one year after the date of grant.

More REGN filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.